Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Yunnan Botanee Bio-Technology Group Co.LTD (300957.SZ)
CNY32.47
+1.47 (+4.74%)
CN SHZ Healthcare Biotechnology
Address
No. 53, Keyi Road 650106
Kunming, CN
Kunming, CN
CEO
Zhenyu Guo
Website
botanee.com.cn
IPO
2021-03-25
ISIN CNE100004G74
Description
Yunnan Botanee Bio-Technology Group Co.LTD operates within the Chinese market, specializing in the development and distribution of a broad spectrum of skincare formulations. Its comprehensive product line encompasses cleansing and makeup removal solutions, facial masks, toners, serums, hydrating moisturizers, eye creams, refreshing facial sprays, sun protection items, cosmetic foundations, and general body care products. This enterprise, founded in 2010, is strategically headquartered in Kunming, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY32.47
+1.47 (+4.74%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
0.65
Float Shares
203.05M
Free Float %
48.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.03% | -0.21% | -7.66% | -19.90% | -8.57% | -4.70% | -14.61% | -59.72% | -86.18% | -76.81% | -76.81% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
32.47
DCF (Unlevered)
51.25
+57.8%
DCF (Levered)
56.78
+74.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
38% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 7 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
6.59
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-6.6% Q1'26: +17.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+0.0% Q1'26: +128.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+14.1% ★ Q1'26: +2.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+11.9% ★ Q1'26: +10.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+19.3% ★ Q1'26: +9.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.5% ★ Q1'26: +1.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.90× ★ Q1'26: 1.91× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 5 EPS Ana. |
Dec 2027 11 Rev. Ana. 6 EPS Ana. |
Dec 2028 9 Rev. Ana. 8 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.64B
est: 2.71B (-2.6%)
|
4.02B
est: 3.92B (+2.7%)
|
5.01B
est: 5.29B (-5.2%)
|
5.73B
est: 5.96B (-3.9%)
|
5.74B
est: 6.37B (-9.9%)
|
5.36B
est: 5.54B (-3.2%)
|
6.01B
5.83B – 6.15B
+8.5% YoY
|
6.62B
6.21B – 6.90B
+10.3% YoY
|
7.22B
7.20B – 7.24B
+9.0% YoY
|
| EBITDA |
659.61M
est: 524.58M (+25.7%)
|
968.11M
est: 759.32M (+27.5%)
|
1.11B
est: 1.02B (+8.4%)
|
954.32M
est: 1.05B (-8.7%)
|
516.08M
est: 1.12B (-53.8%)
|
849.34M
est: 971.18M (-12.5%)
|
1.05B
1.02B – 1.08B
+8.5% YoY
|
1.16B
1.09B – 1.21B
+10.3% YoY
|
1.27B
1.26B – 1.27B
+9.0% YoY
|
| EBIT |
645.86M
est: 497.15M (+29.9%)
|
948.45M
est: 719.61M (+31.8%)
|
1.05B
est: 971.16M (+8.3%)
|
883.60M
est: 943.63M (-6.4%)
|
420.76M
est: 1.01B (-58.3%)
|
634.83M
est: 876.53M (-27.6%)
|
950.98M
923.33M – 973.75M
+8.5% YoY
|
1.05B
982.94M – 1.09B
+10.3% YoY
|
1.14B
1.14B – 1.15B
+9.0% YoY
|
| Net Income |
543.51M
est: 576.42M (-5.7%)
|
862.92M
est: 826.39M (+4.4%)
|
1.05B
est: 1.11B (-5.0%)
|
756.80M
est: 790.55M (-4.3%)
|
503.05M
est: 686.07M (-26.7%)
|
505.72M
est: 543.34M (-6.9%)
|
631.97M
570.18M – 692.41M
+16.3% YoY
|
738.08M
659.51M – 815.44M
+16.8% YoY
|
811.13M
712.46M – 956.86M
+9.9% YoY
|
| SGA |
1.27B
est: 1.38B (-8.4%)
|
1.93B
est: 2.00B (-3.7%)
|
2.39B
est: 2.70B (-11.4%)
|
3.02B
est: 3.00B (+0.8%)
|
3.38B
est: 3.20B (+5.5%)
|
2.37B
est: 2.79B (-14.7%)
|
3.02B
2.93B – 3.09B
+8.5% YoY
|
3.33B
3.12B – 3.47B
+10.3% YoY
|
3.63B
3.62B – 3.64B
+9.0% YoY
|
| EPS |
1.51
est: 1.38 (+9.8%)
|
2.12
est: 1.97 (+7.5%)
|
2.48
est: 2.66 (-6.6%)
|
1.79
est: 1.88 (-4.7%)
|
1.20
est: 1.64 (-26.9%)
|
1.20
est: 1.24 (-2.9%)
|
1.50
1.35 – 1.64
+21.2% YoY
|
1.75
1.56 – 1.93
+16.8% YoY
|
1.99
1.69 – 2.27
+13.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
979.46M
OE per share TTM
2.34
Owner's Yield
6.29%
Maintenance CapEx ratio
6.31%
Maint CapEx / Avg PPE
13.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 25 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.75% | 526.7K | 0.95% |
| 2 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.07% | 24.3K | 0.65% |
| 3 | Franklin FTSE China ETF FLCH | 0.01% | 30.9K | 0.19% |
| 4 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 3.9K | 0.15% |
| 5 | State Street SPDR S&P China ETF GXC | 0.01% | 24.4K | 0.59% |
| 6 | Franklin FTSE China UCITS ETF FLXC.L | 0.00% | 79.4K | 0.19% |
| 7 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 76.3K | 0.17% |
| 8 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 76.3K | 0.17% |
| 9 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 38.7K | 0.26% |
| 10 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 17.2K | 0.48% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
160.5K
Shares Outstanding
421.29M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cheng Hui Bian | Deputy General Manager | — | male |
| Feifei Wang | Deputy General Manager | — | male |
| Long Wang | Deputy GM, Chief Financial Officer & Secretary of Board | — | male |
| Mei Zhang | Deputy GM & Employee Representative Director | — | female |
| Shaoyang Gao | Senior VP & Director | — | male |
| Xiao Jing Wu | Deputy General Manager | — | female |
| Xiao Ma | Senior Vice President & Non-Independent Director | — | male |
| Zhaofeng Liu | Head of Accounting Department & Accounting Supervisor | — | male |
| Zhenyu Guo | GM & Non-Independent Chairman of the Board | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300957.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
